Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Esperion Therapeutics, Inc. < Previous 1 2 Next > Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update August 12, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) August 07, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion to Report Second Quarter 2024 Financial Results on August 12 July 25, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion to Participate in Upcoming BTIG Biotech Conference July 24, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries July 16, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility June 28, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion to Participate in Upcoming June Investor Conferences May 23, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk May 22, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia May 20, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET® May 14, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) May 10, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion Reports First Quarter 2024 Financial Results May 07, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion to Participate in Upcoming May Investor Conferences April 29, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion to Report First Quarter 2024 Financial Results on May 7 April 23, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity April 07, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024 April 01, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference March 26, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24 March 25, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use March 22, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events March 22, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion Reports Fourth Quarter and Full Year 2023 Financial Results February 27, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) February 16, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27 February 13, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR RFK, Esperion Therapeutics Announce 2024 Promotional Schedule February 01, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares January 23, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock January 18, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion Announces Proposed Public Offering of Common Stock January 18, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation January 03, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion to Participate in 42nd Annual J.P. Morgan Healthcare Conference December 18, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet December 13, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.